Breast cancer patients denied life-extending drug in cost rowPatients with advanced breast cancer in the UK are denied Enhertu, a drug that could extend their lives, due to funding decisions by NICE.
Why COVID patients who could most benefit from Paxlovid still aren't getting itPaxlovid's high cost is a barrier to access for many patients.Awareness of Paxlovid's benefits and free access programs is low.